KURA ONCOLOGY INC's ticker is KURA and the CUSIP is 50127T109. A total of 152 filers reported holding KURA ONCOLOGY INC in Q1 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $558,486 | +56.2% | 52,787 | +80.5% | 0.26% | -12.0% |
| Q1 2023 | $357,630 | -82.4% | 29,242 | -82.2% | 0.29% | -75.9% |
| Q4 2022 | $2,036,642 | -24.7% | 164,113 | -17.1% | 1.21% | -21.8% |
| Q3 2022 | $2,706,000 | -32.2% | 198,076 | -9.1% | 1.55% | -35.9% |
| Q2 2022 | $3,994,000 | +68.0% | 217,895 | +47.4% | 2.41% | +59.6% |
| Q1 2022 | $2,377,000 | +106.7% | 147,833 | +80.0% | 1.51% | +65.0% |
| Q4 2021 | $1,150,000 | -13.4% | 82,124 | +15.9% | 0.92% | +4.2% |
| Q3 2021 | $1,328,000 | +65.8% | 70,888 | +84.5% | 0.88% | +54.8% |
| Q2 2021 | $801,000 | -6.2% | 38,428 | +27.2% | 0.57% | -10.6% |
| Q1 2021 | $854,000 | +5.8% | 30,212 | +22.3% | 0.64% | +23.3% |
| Q4 2020 | $807,000 | +6.0% | 24,708 | -0.5% | 0.52% | -7.2% |
| Q3 2020 | $761,000 | +56.9% | 24,833 | -16.5% | 0.56% | +38.1% |
| Q2 2020 | $485,000 | – | 29,741 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,849,947 | $16,871,517 | 9.37% |
| Prosight Management, LP | 1,932,456 | $17,623,999 | 5.58% |
| ACUTA CAPITAL PARTNERS, LLC | 702,093 | $6,403,088 | 4.29% |
| ALETHEA CAPITAL MANAGEMENT, LLC | 350,445 | $3,196,058 | 3.93% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7,335,845 | $66,902,906 | 3.62% |
| Affinity Asset Advisors, LLC | 856,535 | $7,811,599 | 2.20% |
| TCG Crossover Management, LLC | 1,423,642 | $12,983,615 | 1.91% |
| EcoR1 Capital, LLC | 5,806,871 | $52,958,664 | 1.79% |
| BVF INC/IL | 6,730,983 | $61,386,565 | 1.66% |
| DAFNA Capital Management LLC | 550,784 | $5,023,150 | 1.56% |